Evidence map›Paper›PMID 41463212›Full record

ArticleCancers2025

Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer Using Infusional Gemcitabine: Immune Cell Infiltration Analysis and Updated Survival.

Shouki Bazarbashi, Hadeel AlManea, Ali Aljubran, Ahmed Alzahrani, Ali Alqahtani, Fahad Almugbel, Muhammad Shahzad Rauf, Hazem Ghebeh

Abstract read
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shouki BazarbashiCancer Center of Excellence, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.ORCID 0000-0002-8913-8158
Hadeel AlManeaDepartment of Pathology, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.
Ali AljubranCancer Center of Excellence, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.ORCID 0000-0001-9130-2968
Ahmed AlzahraniCancer Center of Excellence, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.
Ali AlqahtaniCancer Center of Excellence, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.
Fahad AlmugbelCancer Center of Excellence, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.
Muhammad Shahzad RaufCancer Center of Excellence, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.
Hazem GhebehInnovation and Research, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.ORCID 0000-0002-3297-3996

Funding

King Faisal Specialist Hospital & Research Centre RAC 2141-124
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

chemoradiotherapygemcitabineimmunerectal cancer

Identifiers

PMID41463212
PMCPMC12730363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.